An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Completed · Phase 1/Phase 2

Conditions studied: Advanced Cancer

In brief

The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in immunotherapy-naive and pretreated populations across select advanced tumor types.

Key facts

Study ID

NCT03459222

Run by

Bristol-Myers Squibb

People needed

229

Starts

2018-05-30

Expected to finish

2025-02-19

Last updated by the study team

2026-04-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologic or cytologic confirmation of select incurable solid malignancies that are advanced (metastatic and/or unresectable), with measurable disease per RECIST v1.1
• Available tumor tissue for biomarker analysis
• Eastern Cooperative Oncology Group Performance Status (ECOG) status of 0 or 1

You may not qualify if…

• Known or suspected central nervous system (CNS) metastases or with the CNS as the only site of active disease
• History of interstitial lung disease / pneumonitis
• Prior malignancy active within the previous 2 years except for locally curable cancers that have been cured, such as basal or squamous cell skin cancer
• Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent
• Other protocol-defined inclusion/exclusion criteria apply

Where it is running

• Local Institution - 0006 — Duarte, California, United States
• Local Institution - 0003 — Aurora, Colorado, United States
• Local Institution - 0004 — Baltimore, Maryland, United States
• Local Institution - 0005 — St Louis, Missouri, United States
• Local Institution - 0001 — Germantown, Tennessee, United States
• Local Institution - 0012 — Wollstonecraft, New South Wales, Australia
• Local Institution - 0011 — Nedlands, Western Australia, Australia
• Local Institution - 0017 — Marseille, France
• Local Institution - 0016 — Toulouse, France
• Local Institution - 0015 — Villejuif, France
• Local Institution - 0010 — Forlì, Italy
• Local Institution - 0009 — Naples, Italy
• Local Institution - 0023 — Rome, Italy
• Local Institution - 0019 — Barcelona, Spain
• Local Institution - 0021 — Madrid, Spain
• Local Institution - 0018 — Madrid, Spain
• Local Institution - 0022 — Málaga, Spain
• Local Institution - 0020 — Pamplona, Spain
• Local Institution - 0008 — Lausanne, Switzerland
• Local Institution - 0007 — Zurich, Switzerland
• Local Institution - 0013 — Headington, United Kingdom
• Local Institution - 0014 — Newcastle upon Tyne, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.